Why The New Topical Hair Loss Drug 'Breezula' Has The Most Promise Since Finasteride!

Breezula® (Clascoterone): 3 reasons I’m optimistic—and 3 limits you should weigh before you get excited.

As a hair loss physician, I explain why this European topical androgen-receptor (AR) blocker could become a leading on-scalp option for androgenetic alopecia (AGA)—and I balance that with three practical limitations to keep expectations realistic.

Why I’m bullish on Breezula
- Long runway of study: Over a decade of clinical development with multi-month and 12-month readouts gives a clearer view of consistency and tolerability than most newcomers.
- No sexual side effects reported in trials to date: A key differentiator versus systemic DHT blockers for patients concerned about libido/ED.
- Promising efficacy signals: Dose-responsive improvements in target-area hair metrics with generally good local tolerability—especially compelling as part of combination approaches (e.g., with minoxidil).

3 limitations (reality check)
- Topical only: On-scalp delivery may be less potent than oral anti-androgens for some patients; adherence and application quality matter.
- Cost: Early signals suggest it may be pricey, which affects long-term accessibility and adherence.
- Steroidal molecule: As a steroidal anti-androgen, there are long-term use considerations (e.g., ongoing monitoring for local effects), even with the favourable trial safety so far.

Who this is for:
Patients and clinicians comparing Breezula (clascoterone/CB-03-01) with minoxidil, finasteride, dutasteride, and other emerging topicals—looking for an evidence-based, balanced overview.

Disclaimer: Educational content only; not medical advice. Individual results vary. Please consult a licensed clinician for personal diagnosis and treatment.

Видео Why The New Topical Hair Loss Drug 'Breezula' Has The Most Promise Since Finasteride! канала Dr Jonathan Hopkirk